Septerna Selects SEP-204 as Candidate for Graves’ Disease and TED
Septerna selected SEP-204 as a development candidate and plans a Phase 1 trial in Q1 2027. The company reported promising preclinical findings.
Related stories
SpaceX Starship Returns to Landing Pad After 22-Hour Orbital Voyage
SpaceX’s Starship returned from a 22-hour voyage in orbit and was caught by mechanical arms at the Texas launch tower, a first for the spacecraft.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
SpaceX Starship Returns to Landing Pad From Orbit
SpaceX’s Starship returned to its landing pad from orbit, completing a test of reusable rockets.
M impact | EQUITY | Nov 14, 2026, 10:39 PM UTC
Air Travel Disruptions to Persist Into Sunday, Officials Say
Officials say thousands of flights have been affected, with air travel issues expected to persist well into Sunday.
M impact | EQUITY | Nov 14, 2026, 09:39 PM UTC
SpaceX Starship Returns to Texas Launch Tower After Orbital Flight
SpaceX’s Starship spacecraft returned Saturday to the Texas launch tower from which it launched a day earlier, completing the rocket system’s first key recovery, according to the r
M impact | EQUITY | Nov 14, 2026, 09:22 PM UTC
More Than 10,000 Flights Delayed or Canceled Saturday
Airlines are working to restore normal schedules.
M impact | EQUITY | Nov 14, 2026, 07:34 PM UTC
Flight Cancellations Mount at DFW and Love Field After FAA Ground Stop
Cancellations mounted Saturday morning at DFW International Airport and Dallas Love Field after an FAA ground stop was lifted.
M impact | EQUITY | Nov 14, 2026, 07:03 PM UTC